
Nidec Announces That Its Board Authorizes Share Repurchase Plan
Reason for Share Repurchase
To flexibly implement share repurchases while considering factors such as funds for medium- to long-term growth investments, the current cash position, stock price levels, and the status of total shareholder returns, with a view to achieving a total return ratio of 50%.
Details of Authorized Share Repurchase Plan
Class of shares: Common stock
Total number of shares that may be repurchased: Up to 13,000,000 shares
(1.13% of total number of shares issued, excluding treasury stock)
Total repurchasable amount: 35 billion yen
Period of repurchase: From May 28, 2025 through May 27, 2026
Reference
Total number of shares issued and outstanding shares held in treasury as of April 30, 2025:
Total number of shares issued (excluding treasury stock): 1,146,307,799 shares
Shares held in treasury: 46,261,137 shares
Cautionary Statement Concerning Forward-Looking Information
This press release contains forward-looking statements regarding the Company's current intent, plans, expectations and estimates. Such forward-looking statements are not guarantees of future performance or events and involve risks and uncertainties. Actual results may differ materially from those described in such forward-looking statements as a result of various factors, including, but not limited to, available funds, future alternative uses for cash, future competing investment opportunities, and general economic, business and market conditions. The Company assumes no obligation to, and does not currently intend to, update these forward-looking statements, except as required by law.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
5 minutes ago
- Business Wire
Luigi de Vecchi to Join Evercore's European Advisory Practice
LONDON--(BUSINESS WIRE)--Evercore (NYSE: EVR) announced today that Luigi de Vecchi will be joining the firm in September 2025 as senior managing director and chairman of its continental European advisory business. He will be based in Milan, Italy, where Evercore is in the process of opening an office. Mr. de Vecchi brings over 35 years of investment banking experience to Evercore and has advised on some of Europe and Italy's largest and most high-profile transactions. At Evercore, he will spearhead the buildout of the firm's presence in Italy, and Europe more broadly. He will work in close partnership with Evercore's existing team in Paris, focusing on the firm's large European and global strategic clients. "I am delighted to join Evercore and collaborate with such a talented group of like-minded, exceptional professionals. I am eager to contribute to the firm's ambitious growth plans in Europe and beyond," said Mr. de Vecchi. Matthew Lindsey-Clark, co-head of Evercore's EMEA investment banking business, said, 'Luigi brings a wealth of experience and senior strategic relationships that complement Evercore's already strong presence across Europe as well as the firm's expansion plans going forward.' Mr. de Vecchi joins Evercore from Citigroup, where he was chairman of continental Europe for corporate and investment banking. Prior to joining Citi in 2012, he was global co-head of investment banking at Credit Suisse, and previously worked at Goldman Sachs and Kleinwort Benson. Mr. de Vecchi received his MA in Business Studies and Economics from the L.U.I.S.S. University in Rome, where he is currently a finance professor and member of the advisory board. He is chairman of Fondazione Sylva, a charity focused on reforestation, and a member of the advisory board of both Save the Children Italia and Fondazione Nuovo Millennio. About Evercore Evercore (NYSE: EVR) is a premier global independent investment banking advisory firm. We are dedicated to helping our clients achieve superior results through trusted independent and innovative advice on matters of strategic and financial significance to boards of directors, management teams and shareholders, including mergers and acquisitions, strategic shareholder advisory, restructurings and capital structure. Evercore also assists clients in raising public and private capital, delivers equity research and equity sales and agency trading execution, and provides wealth and investment management services to high-net-worth and institutional investors. Founded in 1995, the firm is headquartered in New York and maintains offices and affiliate offices in major financial centers in the Americas, Europe, the Middle East and Asia. For more information, please visit


Business Wire
5 minutes ago
- Business Wire
Luigi de Vecchi to Join Evercore's European Advisory Practice as Firm Continues to Build in Europe
LONDON--(BUSINESS WIRE)--Evercore (NYSE: EVR) announced today that Luigi de Vecchi will be joining the firm in September 2025 as senior managing director and chairman of its continental European advisory business. He will be based in Milan, Italy, where Evercore is in the process of opening an office. Mr. de Vecchi brings over 35 years of investment banking experience to Evercore and has advised on some of Europe and Italy's largest and most high-profile transactions. At Evercore, he will spearhead the buildout of the firm's presence in Italy, and Europe more broadly. He will work in close partnership with Evercore's existing team in Paris, focusing on the firm's large European and global strategic clients. "I am delighted to join Evercore and collaborate with such a talented group of like-minded, exceptional professionals. I am eager to contribute to the firm's ambitious growth plans in Europe and beyond," said Mr. de Vecchi. Matthew Lindsey-Clark, co-head of Evercore's EMEA investment banking business, said, 'Luigi brings a wealth of experience and senior strategic relationships that complement Evercore's already strong presence across Europe as well as the firm's expansion plans going forward.' Mr. de Vecchi joins Evercore from Citigroup, where he was chairman of continental Europe for corporate and investment banking. Prior to joining Citi in 2012, he was global co-head of investment banking at Credit Suisse, and previously worked at Goldman Sachs and Kleinwort Benson. Mr. de Vecchi received his MA in Business Studies and Economics from the L.U.I.S.S. University in Rome, where he is currently a finance professor and member of the advisory board. He is chairman of Fondazione Sylva, a charity focused on reforestation, and a member of the advisory board of both Save the Children Italia and Fondazione Nuovo Millennio. About Evercore Evercore (NYSE: EVR) is a premier global independent investment banking advisory firm. We are dedicated to helping our clients achieve superior results through trusted independent and innovative advice on matters of strategic and financial significance to boards of directors, management teams and shareholders, including mergers and acquisitions, strategic shareholder advisory, restructurings and capital structure. Evercore also assists clients in raising public and private capital, delivers equity research and equity sales and agency trading execution, and provides wealth and investment management services to high-net-worth and institutional investors. Founded in 1995, the firm is headquartered in New York and maintains offices and affiliate offices in major financial centers in the Americas, Europe, the Middle East and Asia. For more information, please visit


Business Wire
35 minutes ago
- Business Wire
ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone ® Lispro (THDB0206 injection) in People with T2D
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the 'Company'), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announces that its partner Tonghua Dongbao releases today positive topline results on the Phase 3 clinical trial on BioChaperone ® Lispro (THDB0206 injection), a novel Ultra-Rapid Insulin formulation. Conducted by Tonghua Dongbao, this Phase 3 study (NCT05834868) was approved by the Chinese Regulatory Authorities (CDE 1). The randomized, open, multicenter study evaluated the safety and efficacy of THDB0206 injection compared to Humalog ® in adults with Type 2 diabetes. Dr LENG Chunsheng, President of Tonghua Dongbao, said: " THDB0206 injection is a new generation of ultra-rapid insulin that has demonstrated benefits for improving blood glucose control of adults with Type 2 diabetes compared with the standard of care Humalog ®. Tonghua Dongbao is committed to continue to innovate in the treatment of diabetes and obesity." Olivier Soula, CEO and Co-Founder of Adocia, added: " We are thrilled to share the positive results obtained with BioChaperone ® Lispro on this Phase 3 clinical trial on people with Type 2 diabetes. Given the well-known challenges in showing clinical improvement in this population with a new prandial insulin, we are particularly delighted with these findings. This milestone demonstrates Adocia's ability to advance its innovative treatments to the final stages of clinical development, within strategic partnerships. We congratulate Tonghua Dongbao's team for the quality of execution of a large Phase 3 trial of over 1,000 people.' Results A total of 1,040 Chinese adults with Type 2 diabetes with inadequate glycemic control and using daily multiple injections of insulin were randomized. After 26 weeks of treatment, HbA1c decreased significantly in both groups compared to the baseline. The reduction in the THDB0206 injection group was comparable to that of the Humalog ® group, meeting the primary endpoint. The key secondary endpoints were also demonstrated, with a statistically significant lower rise of blood glucose after a standard meal for the THDB0206 injection group, compared to the Humalog ® group. The 10-point self-monitoring blood glucose (SMBG) of patients at week 26, an important supportive endpoint of the trial, confirmed the advantage of this product in controlling postprandial blood glucose fluctuations, with a statistically improved daily blood glucose level. A series of prespecified subgroup analyzes of the primary HbA1c endpoint also fully confirmed the benefits of this product in long-term blood glucose control in patients with Type 2 diabetes. In addition, the safety and tolerability of THDB0206 injection were good. Most of the adverse events were mild or moderate, and the incidence of adverse events and hypoglycemic events were similar to those of Humalog ®. About BioChaperone ® Lispro BioChaperone ® Lispro was licensed to Tonghua Dongbao in 2018, as part of a Licensing Agreement covering China and other Asian countries 2. BioChaperone ® Lispro is an Ultra-Rapid Insulin, belonging to the latest generation of prandial insulins. It combines Adocia's proprietary BioChaperone ® technology with insulin lispro, the active ingredient in the standard of care, Humalog ® (Eli Lilly). This innovative formulation acts significantly faster than earlier insulin generations, effectively reducing post-meal hyperglycemia, which is a key contributor to long-term complications such as retinopathy, diabetic foot ulcers, or kidney failure. Additionally, its rapid elimination minimizes the risk of hypoglycemia, often caused when insulin level remains high after post-meal glucose levels have normalized. The faster action profile of BioChaperone ® Lispro associated to an excellent local tolerance enhances its compatibility with modern diabetes management systems, particularly insulin pump systems, and provides better integration into advanced treatment algorithms. Beyond its clinical advantages, the quick onset of BioChaperone ® Lispro improves quality of life by offering greater flexibility in dose timing. Patients can administer insulin at mealtime, or even right-after-mealtime, allowing for more accurate dosing based on known meal timing and content. This reduces the risks of overdosing or underdosing, which can lead to hypo- or hyperglycemia and their associated complications. The simplified dosing process eases the psychological burden on patients and caregivers, significantly alleviating the stress associated with diabetes management. About Tonghua Dongbao Tonghua Dongbao Pharmaceutical Co. Ltd (SHSE: 600867), is a pharmaceutical company based in Jilin province, China, specializing in the R&D, manufacturing and commercialization of insulins and other diabetes treatments. Tonghua Dongbao currently employs over 3,000 people and has sales of around $280 million. It has been listed on the Shanghai Stock Exchange since 1994, with a market capitalization of about $2.3 billion. About Adocia Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone ® technology for the development of new generation insulins and products combining different hormones; 2) AdOral ®, an oral peptide delivery technology; 3) AdoShell ®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel ®, a long-acting drug delivery platform. Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext ™ Paris (Euronext: ADOC; ISIN: FR0011184241). Disclaimer This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those set forth in the 'Risk Factors' section of the universal registration document that was filed with the French Autorité des marchés financiers on April 29, 2025, available at Those risks include uncertainties inherent in Adocia's short- or medium-term working capital requirements, in research and development, future clinical data, analyses and the evolution of economic conditions, the financial markets and the markets in which Adocia operates, which could impact the Company's short-term financing requirements and its ability to raise additional funds.